News
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Novo Nordisk stock slumped early Monday as the drugmaker was facing a hit to revenue from several different directions. This ...
Novo Nordisk A/S trimmed its forecasts as sales of the drugmaker’s blockbuster obesity and diabetes medicines struggle with ...
Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback